ArticleDrug delivery and translational research2026
Mannose receptor-targeted MSC-derived exosomes as a high-affinity delivery platform for liver sinusoidal endothelial cells.
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Liver sinusoidal endothelial cells (LSECs) play a crucial role in the progression of liver fibrosis. While mesenchymal stem cell-derived exosomes (MSC-Exos) hold potential for liver regeneration, their therapeutic efficacy is often limited by poor target specificity and rapid clearance. Here, we developed mannose receptor-targeting MSC-Exos (Man-Exos) by incorporating DSPE-PEG-Mannose via a post-insertion method to enhance LSEC-specific delivery. The physicochemical stability and targeting efficiency of Man-Exos were evaluated both in vitro and in vivo. Man-Exos exhibited high stability in various conditions and showed significantly enhanced binding affinity to LSECs compared to non-targeted exosomes. Notably, in a co-culture system of LSECs and macrophages, Man-Exos demonstrated superior selectivity for LSECs. In vivo biodistribution studies further confirmed that Man-Exos predominantly accumulated in the liver, specifically colocalizing with LSECs for up to 48 h. Our findings suggest that Man-Exos can serve as a highly efficient and stable delivery platform for LSEC-targeted therapy, providing a promising strategy for enhancing the translational potential of exosome-based regenerative medicine in liver fibrosis.
Indexed as
Identifiers
42360611What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.